Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters sold 6,226 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $19.67, for a total value of $122,465.42. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of Amphastar Pharmaceuticals, Inc. (AMPH) traded down $0.21 during mid-day trading on Tuesday, reaching $18.68. The company had a trading volume of 155,072 shares, compared to its average volume of 293,490. The stock has a market cap of $881.82, a price-to-earnings ratio of 127.87 and a beta of 1.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. Amphastar Pharmaceuticals, Inc. has a one year low of $12.05 and a one year high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.05. The company had revenue of $57.90 million during the quarter, compared to analyst estimates of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The firm’s quarterly revenue was down 9.8% on a year-over-year basis. During the same quarter last year, the business posted $0.14 EPS. equities analysts predict that Amphastar Pharmaceuticals, Inc. will post -0.03 earnings per share for the current year.

Amphastar Pharmaceuticals declared that its Board of Directors has initiated a share buyback program on Wednesday, August 9th that permits the company to repurchase $20.00 million in shares. This repurchase authorization permits the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Several brokerages have recently commented on AMPH. Piper Jaffray Companies reiterated a “buy” rating and set a $19.00 price objective on shares of Amphastar Pharmaceuticals in a report on Sunday, September 17th. Needham & Company LLC increased their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a report on Friday. Jefferies Group reiterated a “buy” rating and set a $19.00 price objective (down previously from $20.00) on shares of Amphastar Pharmaceuticals in a report on Friday, August 11th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Finally, BidaskClub lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $20.86.

A number of hedge funds have recently modified their holdings of the stock. Nationwide Fund Advisors raised its stake in shares of Amphastar Pharmaceuticals by 11.9% during the 2nd quarter. Nationwide Fund Advisors now owns 49,266 shares of the company’s stock valued at $880,000 after buying an additional 5,233 shares during the last quarter. Northern Trust Corp raised its stake in shares of Amphastar Pharmaceuticals by 2.0% during the 2nd quarter. Northern Trust Corp now owns 485,706 shares of the company’s stock valued at $8,675,000 after buying an additional 9,672 shares during the last quarter. Argent Capital Management LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at about $1,069,000. Schwab Charles Investment Management Inc. raised its stake in shares of Amphastar Pharmaceuticals by 7.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 218,080 shares of the company’s stock valued at $3,895,000 after buying an additional 14,646 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Amphastar Pharmaceuticals by 32.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,061,188 shares of the company’s stock valued at $15,388,000 after buying an additional 260,288 shares during the last quarter. Institutional investors own 44.14% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/05/amphastar-pharmaceuticals-inc-amph-cfo-sells-122465-42-in-stock.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.